Aureka Biotechnologies, an AI-native TechBio company, has closed a US$100 million Series B financing round, bringing its total capital raised to nearly US$200 million. The funding was led by Granite Asia and a prominent strategic investor, with participation from HighLight Capital and existing shareholders. This investment will fuel the advancement of the company's generative AI platform for therapeutic discovery.
Strategic Allocation of New Capital
The company will direct the proceeds toward research and large-scale training of its next-generation biological foundation models. This initiative aims to enhance performance on critical tasks like de novo molecular design, structure modeling, and function prediction. Ultimately, this strengthens the intelligence core of Aureka's entire drug discovery system.
Aureka will also upgrade its experiment-centered feedback engine, known as "Lab-in-the-Loop". This enhancement will fortify the closed-loop connection between its AI models and proprietary experimental platforms. The integration ensures a seamless cycle of digital design and physical validation for accelerated development.
Pioneering a Closed-Loop AI Infrastructure
Founded in 2023, Aureka is developing a system that combines AI models, agents, and digital biology to redesign the drug discovery process. The company's infrastructure is built on the principle that biological understanding requires constant feedback from the physical world. This approach moves beyond pure computation to create a more effective research engine.
The "Lab-in-the-Loop" mechanism treats the laboratory as a core component of how the AI learns and improves. Models propose testable molecular designs, the experimental platform generates high-quality functional data, and results feed back to refine the models. This continuous design-validate-learn cycle allows the system to evolve with each experiment.
Validated Models and Commercial Progress
This integrated infrastructure has produced AuraIDE, Aureka's proprietary biological foundation model trained on internal protein data. Its capabilities in structure prediction and molecular design have been confirmed by third-party evaluations of its open-source version, OpenDDE. These results position Aureka's models among the leaders in the biomolecular AI field.
The company has successfully translated its platform's capabilities into tangible commercial outcomes and high-value drug assets. Aureka has established strategic partnerships with several leading global pharmaceutical firms to develop differentiated antibody therapeutics. These collaborations have already generated significant revenue, validating the platform's scalability and potential.
Vision for a Biological World Model
According to founder and CEO Dr. Weian Zhao, this approach creates a next-generation drug discovery engine. The company's long-term vision is to build a "biological world model" capable of simulating complex molecular interactions. This would enable AI agents to autonomously plan, execute, and iterate on drug design tasks.
Investor confidence underscores the potential of Aureka's strategy. Partners like Granite Asia and HighLight Capital highlighted the company's complete AI-native infrastructure and the efficiency of its closed-loop system. They believe Aureka is well-positioned to redefine the paradigm for biologics R&D and achieve global growth.
With its new US$100 million in funding, Aureka Biotechnologies is poised to accelerate the evolution of its AI-driven drug discovery platform. The company's focus on integrating advanced biological models with a closed-loop experimental system represents a significant step toward simulating biological systems. This innovative approach promises to push the boundaries of AI in the life sciences industry.